Kazia Therapeutics Announced The Early Conclusion Based On Safety And Clinical Response Findings Observed To Date From A Two-part Phase 1 Trial Of Paxalisib With Radiation Therapy For PI3K Pathway Mutation Brain Metastases From Solid Tumors
Kazia Therapeutics根據迄今爲止在一項由兩部分組成的Paxalisib的1期試驗中觀察到的安全性和臨床反應結果宣佈了早期結論，該試驗採用了針對實體瘤的PI3K途徑突變腦轉移的放射治療